Navigating Risk in Life Sciences: Building Resilience to Support Growth

Life sciences companies need to work with all their partners to ensure that they are leveraging AI responsibly and to its full potential while upholding regulatory compliance. The ability to bring new therapies quickly to market, improve diagnostic accuracy, and reduce research and development costs are helping to transform and accelerate drug discovery and personalized medicine. GenAI can also increase the efficiency of clinical trial designs by selecting ideal candidates and predicting trial outcomes, which can translate to higher success rates in drug development.

• As the price of sequencing genomes declines, the ability to support personalized healthcare and gene therapy at scale will continue to grow.
• Legacy processes, demand volatility and increasing data scale and complexity demand a new approach.
• Pre-digital facilities with manual processes supported by expensive labor will no longer be the norm.
• Within drug companies focused on AI-based discovery, there is publicly available information on about 160 discovery programs, of which 15 products are reportedly in clinical development.
• Well-defined technology and data strategies, along with change management and talent identification programs, are key to success.
• These capabilities will fundamentally change the role of finance organizations by emphasizing speed of insight, adoption of data-driven decision making and scaling of analytics within the enterprise.

Research shows that companies with greater diversity are more likely to outperform their competitors, making diversity a key factor in organizational success. Diverse teams bring different perspectives, drive innovation, and enhance problem-solving capabilities. International recruitment is another option, but it requires careful navigation of labor laws and cultural differences. To overcome talent shortages, companies can offer remote work options, relocation packages, or form partnerships with local academic institutions to build talent pipelines.

However, you must still account for regulatory confines, maintain quality standards and good manufacturing practices, and ensure an effective and efficient commercialization workflow in the process. This can result in increased market share and first-to-market revenue advantages, offsetting some development costs. In addition, replacing retiring employees with skilled new ones was cited as the number one workforce challenge by life sciences CEOs in a recent survey by KPMG. It’s essential to evaluate where your company stands with each — and decide on a course challenges in life sciences industry of action that will enable you to move forward and see progress in the year ahead. Promoting work-life balance and continuous learning also plays a crucial role in keeping employees engaged and committed.

Embedding cybersecurity in every aspect of the technologies and processes of life sciences is therefore essential. With the excitement and promise of innovative technologies powering discoveries in the industry, life sciences companies need to prioritize cybersecurity to avoid the impact of cyberattacks on progress. However, despite these challenges, only 44% of life sciences companies are currently leveraging technology to calculate how scenarios such as these will impact their supply chains and outcomes (Supply Chain Management Review, 2024). This, coupled with the impact of regulations, necessitates life sciences companies to reconsider their supply chain strategies. This empowers life sciences companies to enhance their decision-making across the drug development lifecycle.

Shifts in the evolving content delivery models

Most importantly, it improves health outcomes through condition-specific guidance, medication reminders and treatment adherence support. Personalization also supports regulatory compliance by ensuring communications are tailored with accurate and legally compliant information. In addition, replacing retiring employees with skilled new ones was cited as the number-one workforce challenge by life sciences CEOs in a recent survey by KPMG. Consistent branding serves to improve brand recognition, create trust, and increase customer loyalty. Standardizing messaging, materials, and specifications across multiple channels is critical — especially if you’re currently offshoring or nearshoring production.

Emerging AI legislation and digital health regulations add further complexity, particularly around data integrity and automated decision-making. In 2025, manufacturers and logistics leaders face a volatile mix of global disruptions, tighter regulations, and rapid digital change. With collaboration, innovation, and a commitment to both ethical and sustainable practices, the life sciences sector is poised to usher in a new era of progress and prosperity. Protecting these innovations through patents is crucial for ensuring a return on investment. On one hand, companies need to recoup their substantial R&D investments, which often leads to high pricing for novel treatments. This high attrition rate represents not just a scientific challenge but also a financial one, with companies often investing billions with no guarantee of a return.

Low success rates in clinical trials and high attrition rates make R&D a high-risk area. Navigating the constantly evolving landscape of global regulations, including FDA, EMA, and ICH guidelines, is complex and resource-intensive. Consistent branding serves to improve brand recognition, create trust and increase customer loyalty. Standardizing messaging, materials and specifications across multiple channels is critical, especially for companies currently offshoring or nearshoring production.

Aon is in the business of better decisions.

GenAI’s traction in the marketplace is largely the result of improvements to large language models (LLMs) that have accelerated training and compiling with vast amounts of complex data. The life sciences industry has been leveraging artificial intelligence (AI) long before its current popularity. While it faces significant challenges, there are ample opportunities to transform through technology, strategic collaboration, and a relentless focus on the patient.

This article provides an in-depth exploration of the current landscape, shedding light on both the obstacles and the immense opportunities within the life sciences sector. The life sciences industry, encompassing a vast array of disciplines from biotechnology to pharmacology, stands as a beacon of innovation and progress. How to Get Your Buyers to Contact You First Learn how to engage buyers early in the decision-making process with personalized content, brand strategies, and competitive positioning. 7 Reasons Why Your B2B Content Marketing Strategy Is Not Working Discover the seven common pitfalls in B2B content marketing strategies and gain actionable insights to create content that aligns with buyer needs, supports decision making, and enhances brand credibility. INFUSE Named an OpenAI Select Partner INFUSE is now an OpenAI Select Partner, helping B2B organizations build, deploy, and scale AI solutions. By working closely with their cybersecurity partners, life sciences companies can focus on the development of novel therapeutics and innovative medical devices, with greater peace of mind.